bitFlyer Makes Cryptocurrency Trading Even Easier with Launch of bitFlyer App
21.10.2019 08:00:00 EEST | Business Wire | Press release
Today, leading cryptocurrency exchange bitFlyer has announced the launch of the bitFlyer app across Europe and the USA. The app, available for free on both iOS and Android, will allow users to buy and sell Bitcoin (BTC), Ethereum (ETH), Litecoin (LTC), Bitcoin Cash (BCH), Ethereum Classic (ETC), Monacoin (MONA) and Lisk (LSK).1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191020005009/en/
bitFlyer app iOS
The bitFlyer app will make it even easier for users to buy and sell, whilst still adhering to the same robust KYC and verification standards as the bitFlyer website.
Since 2014, bitFlyer has been trusted by millions across the globe as the most secure platform to easily buy and sell cryptocurrencies, and remains the only exchange licensed to operate across the US, Japan and Europe combined. This app launch is the latest development in a major growth strategy by the European and US businesses, to match what is already available to millions of bitFlyer Japan customers, where bitFlyer is recognised as a household name and one of the longest-standing cryptocurrency exchanges.
Yuzo Kano, bitFlyer founder and CEO of bitFlyer USA, said: “With the new bitFlyer apps, we are bringing the reliability, security and experience of Japan's market leader to our European and American customers, closing the gap between our service offerings and creating a truly global and regulated exchange product.”
Andy Bryant, Co-head and COO at bitFlyer Europe, said: “With our Buy/Sell platform, we strived to create a simpler, faster and even more transparent experience where everyone can buy cryptocurrencies in just a few minutes and from a reputable source. Now with the bitFlyer app, this is even more convenient for users.
We are staying true to our mission of making the world simpler with blockchain, by making the transparency, security and simplicity of our robust trading platforms available via a quick, single app download.”
Buy instantly and securely
The bitFlyer app was created with users in mind, making it even easier for those who prefer navigating from a smartphone to buy and sell cryptocurrencies. Current bitFlyer users can log on to the app with their existing account details, while new traders can register by using an email address, and inputting the relevant information for KYC procedures to deposit and begin trading.
Other features of the bitFlyer app include:
● Users are shown real-time price data, notified about the latest market movements and given access to the latest cryptocurrency news without leaving the app, encouraging users to always stay on top of the market and make informed decisions
● Users can clearly follow their position, making it even easier to keep track of profit and loss (PnL), view trade history and seamlessly visualise their portfolio
● Users can now simply scan a QR code to send and receive virtual currencies with bitFlyer
● From October 21st to October 27th, new customers downloading the bitFlyer app and registering a new verified account will receive €10 (or $10 if based in the US) in BTC without any deposit required.
Key features:
● Buy Bitcoin, Ethereum, Litecoin and more in just a few taps using USD, EUR, or JPY 2
● See real-time price data and get notified about market movements
● Added news functionality allows users to access the latest industry news without leaving the app
bitFlyer launched in the USA in November 2017, followed by bitFlyer Europe in January 2018, both as fully owned subsidiaries of bitFlyer, Inc., a household name in the cryptocurrency space in Japan and one of the longest-standing cryptocurrency exchanges. It is the only cryptocurrency exchange to be licenced in Japan, the US and Europe combined, and has also recently been recognised as one of only 10 exchanges that isn’t faking trading volumes.
bitFlyer is passionate about the future of the cryptocurrency industry and aims to support that future by setting the global standard for exchanges. It believes that standards and regulations are fundamental to the future of the industry and is often involved in conversations at the highest level, including having taken part in the recent G20 discussions. It was also involved in the amendment to the Payments Act in Japan which famously recognised bitcoin as legal tender.
The company continues to build out its product portfolio in line with its vision to break down barriers of entry that many face while accessing cryptocurrency. bitFlyer Japan already offers a wide range of products, and the addition of new Apps in the US and EU is the beginning of the brand’s ambition to expand access to cryptocurrency on a global scale.
ENDS
About bitFlyer EUROPE S.A.
bitFlyer EUROPE S.A. is a wholly-owned subsidiary of bitFlyer, Inc., a leading bitcoin and blockchain company based in Japan. The European office is located in Luxembourg and operates an exchange platform for European traders to buy and sell cryptocurrencies. bitFlyer EUROPE S.A. site: https://bitflyer.com/en-eu/
About bitFlyer USA, Inc.
bitFlyer USA, Inc. is a wholly-owned subsidiary of bitFlyer, Inc., a leading Bitcoin and blockchain company based in Japan. The US office is located in San Francisco and operates an exchange platform for US traders to buy and sell cryptocurrencies. Launching in the U.S. in 2017, bitFlyer USA currently operates in 46 states and territories, including New York as a holder of the New York Bitlicense. bitFlyer USA, Inc., site: https://bitflyer.com/en-us/
1MONA and LSK available in Europe and Japan only.
2 Depending on jurisdiction
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191020005009/en/
Contact information
Lauren Armour
Tyto PR
07826 557 326
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom